In an amended 13D filing on Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), hedge fund Sarissa Capital Management, which holds a 6.46 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE